AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma
Abstract Background Glioblastoma is an aggressive brain cancer, usually of unknown etiology, and with a very poor prognosis. Survival from diagnosis averages only 3 months if left untreated and this only increases to 12–15 months upon treatment. Treatment options are currently limited and typically...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMC
2024-07-01
|
| 叢編: | BMC Cancer |
| 主題: | |
| 在線閱讀: | https://doi.org/10.1186/s12885-024-12631-w |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|